利用表面增强拉曼光谱对前列腺分泌液和血清进行评估以用于前列腺癌的无创检测：一项初步研究
Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study.
作者信息
Shao Xiaoguang, Pan Jiahua, Wang Yanqing, Zhu Yinjie, Xu Fan, Shangguan Xun, Dong Baijun, Sha Jianjun, Chen Na, Chen Zhenyi, Wang Tingyun, Liu Shupeng, Xue Wei
机构信息
Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China.
Key Laboratory of Specialty Fiber Optics and Optical Access Networks, School of Communication and Information Engineering, Shanghai University, Shanghai, PR China.
出版信息
Nanomedicine. 2017 Apr;13(3):1051-1059. doi: 10.1016/j.nano.2016.12.001. Epub 2016 Dec 13.
Surface-enhanced Raman spectroscopy (SERS) involving expressed prostatic secretion (EPS) and serum was investigated; the objective was to determine if this approach could distinguish prostate cancer from benign prostatic hyperplasia. A total of 120 SERS spectra for EPS and 96 spectra for serum were gathered from patients within a prospective contemporary biopsy cohort. Significant differences in spectra between prostate cancer and benign prostatic hyperplasia were tentatively assigned to component changes in EPS and serum samples. Principal component analysis and linear discriminate analysis were utilized to evaluate the spectral data for EPS and serum, to build diagnostic algorithms. The leave-one-out cross-validation method was used to validate the diagnostic algorithms; it revealed diagnostic sensitivities of 75% and 60%, specificities of 75% and 76.5%, and accuracies of 75% and 68% for EPS and serum, respectively. The results suggest that EPS and serum SERS analysis could be a potential tool for prostate cancer detection.
对涉及前列腺分泌物（EPS）和血清的表面增强拉曼光谱（SERS）进行了研究；目的是确定这种方法能否区分前列腺癌和良性前列腺增生。在前瞻性当代活检队列中，从患者那里收集了总共120份EPS的SERS光谱和96份血清光谱。前列腺癌和良性前列腺增生之间光谱的显著差异初步归因于EPS和血清样本中的成分变化。利用主成分分析和线性判别分析来评估EPS和血清的光谱数据，以构建诊断算法。采用留一法交叉验证方法对诊断算法进行验证；结果显示，EPS和血清的诊断敏感性分别为75%和60%，特异性分别为75%和76.5%，准确率分别为75%和68%。结果表明，EPS和血清SERS分析可能是一种检测前列腺癌的潜在工具。
Zotero 插件